Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05913713 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HIIT Following Breast Cancer Chemotherapy

StatusCompleted
PhaseNot applicable
Started2024-03-07
View on ClinicalTrials.gov ↗

Amendment history

2026-09-26
Trial completed
Final enrollment: 37 participants (planned 158)
Primary completion confirmed: May 2026 (last estimated December 2026)
2026-08-26
Study Status, Contacts/Locations v11
Enrollment closed, study ongoing
Primary completion pushed: 2026-05-31 → 2026-12
Completion pushed: 2026-05-31 → 2026-12
Study sitesdetails revised at 1 of 1 site
2025-11-20
Study Status v10
Re-verified, no change to tracked fields
2024-10-22
Study Status, Eligibility v9
Eligibility criteria-114 characters
[...] study findings (e.g., dietary intervention for weight loss) consistent participation over the past 6 months in moderate-intensity aerobic exercise training for ≥150 min/week
2024-07-09
Study Status, Eligibility v8
Eligibility criteria+46 characters
[...] ary artery bypass surgery or angioplasty or coronary stent) lymphedema stage ≥2 prior to study enrollment are pregnant current participation in other experimental int [...]
Show 7 earlier versions
2024-07-02
Study Status, Eligibility v7
Eligibility criteria-288 characters
[...] ating agent and/or taxane) more than 6 months but less than 1218 months prior to study enrollment. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment and during study participation absence of contraindications to exercise or to participate i [...] approval Exclusion Criteria: do not meet inclusion criteria completed chemotherapy and/or other cancer treatment (i.e., surgery or radiation) within past 6 months. Adjuvant end [...] [...]
2024-04-25
Study Status v6
Primary completion date2026-05-25→2026-05-31
Completion date2026-05-25→2026-05-31
Start date2024-03-11→2024-03-07
2024-04-23
Not Yet Recruiting→Recruiting Study Status, Eligibility, Contacts/Locations v5
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2025-05-25→2026-05-25
Completion date2025-05-25→2026-05-25
Start dateestimated 2024-03→confirmed 2024-03-11
Eligibility criteria+317 characters
[...] teria completed chemotherapy and/or other cancer treatment (i.e.g., surgery or radiation) besideswithin past 6 months. Adjuvant endocrine therapy for breast cancer (e.g., ovarian suppression, SERMs, SERDs, AIs), CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bisphosphonates are allowed within 6 months of study enrollment scheduled to receive surgery, radiation therapy, or other cancer treatment besides ovarian suppressionchemotherapy during the study period. Adjuvant endocrine therapy, CDK4/6 inhibitors, PARP inhibitors, HER2 targeted agents, immunotherapy, and bi [...] [...]
Study sitesdetails revised at 1 of 1 site
2024-02-20
Study Status v4
Start date2023-11→2024-03
2023-10-20
Study Status v3
Start date2023-09→2023-11
2023-09-07
Study Status, Eligibility v2
Start date2023-08→2023-09
Eligibility criteria+13 characters
[...] ary artery bypass surgery or angioplasty or coronary stent) are pregnant current participation in other experimental interventions th [...]
2023-08-21
Study Status, Outcome Measures v1
Primary endpoints6 entries, revised
%Percent completed vs. planned exercise duration %Percent completed vs. planned exercise frequency %Percent completed vs. planned exercise intensity
2023-06-13
Original filing
Chemotherapy is an effective breast cancer treatment, which helped to increase the 5-year survival rate to approximately 95%. However, breast cancer survivors have a higher risk of cardiovascular disease (CVD) due to chemotherapy than adults without cancer. Cardiovascular rehabilitation can be an effective strategy to decrease the incidence of CVD and its risk factors in this population. The proposed study may help to examine the effect and durability of a novel high-intensity interval training compared to moderate-intensity continuous training on cardiovascular rehabilitation in breast cancer survivors.
Trial Details
NCT Number NCT05913713
Lead Sponsor University of Florida
Collaborators: National Institute on Aging (NIA)
Conditions Breast Cancer
Enrollment 37 participants
Start Date 2024-03-07
Primary Completion 2026-05-20 (estimated)
Study Completion 2026-05-20 (estimated)
Updated on ClinicalTrials.gov 2026-09-25